Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared Holz

Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzПодробнее

Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее

Novo Nordisk cuts some supply of Wegovy obesity drug as demand growsПодробнее

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzПодробнее

Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentallyПодробнее

Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-termПодробнее

New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesПодробнее

Novo Boosts Profit Outlook on Obesity Drug DemandПодробнее

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B CompanyПодробнее

Drugs for obesity are a massive market, says Mizuho's Jared HolzПодробнее

Novo Nordisk CEO talks soaring weight-loss drug demand, Q1 earningsПодробнее

Obesity drug maker Novo Nordisk lifts outlook again | REUTERSПодробнее

Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%Подробнее

Novo Nordisk CEO on Wegovy, Ozempic Supplies and PricingПодробнее

Novo valuation beats Tesla on experimental obesity drug data | REUTERSПодробнее

Novo Nordisk Sees Obesity Drug Fueling Record ProfitПодробнее

Novo Nordisk CEO on Catalent, Ozempic and WegovyПодробнее

Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA’S MeachamПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее